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Summary
Recent evidence suggests that medically resistant
epilepsy can be identified if seizures persist de-
spite adequate doses of 2 appropriate first-line an-
tiepileptic drugs (AEDs). Patients with medically
resistant epilepsy should have their seizures care-
fully characterized in order to confirm their diagno-
sis, select treatment, and assist in determining
prognosis. Patients should be counseled about fac-
tors that aggravate epilepsy and the importance of
adhering to treatments. Physicians should care-
fully inquire about side effects and alter therapy to
eliminate or minimize these symptoms. Uncon-
trolled seizures cause injuries, disability, and in-
creased mortality, so surgery should be considered
as soon as seizures are proven to be medically re-
sistant. Patients with incomplete response to
AEDs and who are not surgical candidates may
benefit from additional medication trials or from
palliative nonmedical therapies, such as vagal
nerve stimulation.
W
hat is medically resistant epilepsy?
Medically resistant epilepsy would
seem to be a self-evident term, refer-
ring to patients whose seizures persist
despite using antiepileptic drugs (AEDs). The defini-
tion, however, relies as much upon pharmacologic efficacy and physician treatment skills as
the underlying biology and natural history of epilepsy. One might have hoped that the devel-
opment of nearly a dozen new drugs for epilepsy in the 1990s and 2000s would have simpli-
fied this definition. Unfortunately, while many newer drugs have superior pharmacokinetic
and side-effect profiles than older AEDs, they possess the same degree of effectiveness. These
AEDs rarely stop seizures once older agents have failed. Hence, until innovative pharmaceuti-
cal approaches yield better response rates, we must conclude that medical resistance is biolog-
ically determined and innate in some forms of epilepsy.
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Drug-resistant epilepsy has been defined as the “failure of adequate trials of 2 tolerated,
appropriately chosen and used antiepileptic drug schedules (whether as monotherapy or
in combination) to achieve sustained seizure freedom.” This operational definition, estab-
lished by an International League Against Epilepsy commission,1 relies upon the observa-
tion that adults and children rarely achieve sustained seizure freedom once 2 agents have
failed to control seizures.2–4 The definition includes the important requirement that the
drugs must be both appropriate for the patient’s seizure type and tolerated at therapeutic
doses. For example, failure of ethosuximide to control complex partial seizures is not a
valid drug failure since ethosuximide is ineffective for focal seizures. Similarly, a suitable
dose must be used, so the patient who only tolerates a subtherapeutic dose of a particular
AED cannot be considered to have failed to respond to that drug. Finally, the drug must
be given a reasonable chance to work, and an excessively brief course of treatment is not
adequate. Careful attention to these requirements should prevent inappropriate diagnosis
of drug resistance.
Why is it important to recognize medically resistant epilepsy?
Patients with frequent, severe seizures experience high rates of psychosocial disabilities,
including undereducation, underemployment and unemployment, impaired socialization,
and psychiatric disturbances.5,6 They also have increased medical morbidity, with higher than
expected injury rates and high mortality rates.6 Attaining seizure control by nonmedical
means can reverse some of the disability, morbidity, and mortality of refractory epilepsy.7,8
Failure to acknowledge drug resistance may prevent patients from receiving alternative treat-
ments that might be effective, such as epilepsy surgery.
One must consider seizure type, seizure effects, and epilepsy syndrome when thinking
about drug-resistant epilepsy as they influence whether new medications or alternative
therapies are needed. What kinds of seizures merit more aggressive therapy? The most
common types are seizures producing loss of awareness, which can be disabling and pose
medical and psychosocial risk. Uncontrolled complex partial seizures, and, especially,
tonic-clonic seizures are associated with increased mortality, from sudden unexpected
death in epilepsy (SUDEP) and other causes; this risk exceeds the risk of more aggressive
interventions. Some seizures without loss of consciousness might be sufficiently disturb-
ing to warrant pursuing new treatments as well (e.g., seizures producing vomiting or
intense fear).
Seizures that cause injury (e.g., falling) also must be taken more seriously. Seizures with
stigmatizing behavior (e.g., incontinence or disrobing) pose more difficulty than inconspicu-
ous attacks. Similarly, seizures followed by profound postictal effects (e.g., extreme fatigue or
sleepiness, cognitive impairment, or psychiatric disturbances) merit more aggressive therapy.
By contrast, minor nondisabling seizures without these features might be deemed medically
resistant, but are insufficiently problematic to warrant pursuing further diagnostic evaluation
or therapy. The epilepsy syndrome matters, as well. One must establish whether the syndrome
is static or progressive (e.g., progressive myoclonus epilepsy or Rasmussen syndrome) and
whether it is potentially surgically remediable (e.g., mesial temporal sclerosis). Response to
medication must always be put in context, considering what kind of seizures and epilepsy are
present prior to making a decision about the next steps.9
Steps to accurately diagnose and treat medically resistant
epilepsy Confirm the patient has epilepsy (tables 1 and 2) Seizures may not respond to
AEDs if the patient does not have epilepsy. Common imitators of seizures include convulsive
syncope (severe syncope causing jerking or shaking), psychogenic nonepileptic seizures
(seizure-like behaviors), pain or panic reactions, and dissociative states.10 Most seizure types
and epilepsy can be accurately diagnosed by the presence of their typical clinical features. The
EEG can often help confirm the seizure type and MRI is important to identify underlying
causes for seizures. It is important to collect a careful history of key clinical features of seizures
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from both the patient and observers. Here is a helpful list of some of the common features of
seizures: the presence of warning symptoms (gastric or psychic auras are common with complex
partial seizures); the presence of activity arrest, altered awareness, or diminished responsiveness
during the seizure; the duration of the episodes (most epileptic seizures last less than 4 minutes);
and whether the recovery period matches the severity of the seizure (usually several minutes for
mild complex partial seizures, up to hours following tonic-clonic seizures).11 Complex partial
seizures are often preceded by brief epigastric or psychic (e.g., fear, de´ja` vu) auras and may be
associated with activity arrest or with confusion and typical motor automatisms, such as fumbling,
chewing, mild limb shaking, or head/eye deviation with postictal confusion. Tonic-clonic seizures
aremajor convulsive episodes with severe stiffening and shaking and postictal confusion, often with
tongue biting and postictal headaches.
In contrast to seizures, syncopal episodes often occur when patients are standing or
changing posture, particularly when dehydrated or exhausted. Many patients become
pale, briefly lightheaded or dizzy, and then collapse. Patients may experience brief myo-
clonic jerks, or even full convulsions if severely hypotensive.12 Patients often have nausea
and feel exhausted after a syncopal episode—less common features of seizures. Patients
with psychogenic nonepileptic seizures (“pseudoseizures”) often have multiple features
which are atypical for epileptic seizures, such as preictal headache, eye closure or flutter-
ing, asynchronous or writhing movements, a rapid start-stop-start pattern of seizures,
prolonged confusion, and stress triggers.13 Psychogenic seizures often remain misdiag-
nosed when normal variant or drowsy EEG patterns are interpreted as epileptiform dis-
charges.14 Patients with pain reactions or panic reactions often have symptoms which
precede their seizure-like behaviors. Uncertain diagnoses usually can be clarified with
video-EEG.
Determine treatment response (table 3) Patients who fail treatment with high doses of
several first-line AEDs appropriate for their seizure type have medication-resistant epilepsy.
Some patients, however, appear to have drug resistance, but have not tolerated several AEDs
due to multiple allergic reactions or due to drug side effects. These patients can usually find
alternative therapies which they can tolerate. AEDs infrequently associated with allergic reac-
tions are levetiracetam, topiramate, gabapentin, and divalproex.15 Many patients, particularly
the elderly, are sensitive to CNS-related medication side effects, such as dizziness, somnolence,
and imbalance.16 They often tolerate and respond to treatment with standard AEDs if AEDs
are titrated very slowly to low doses.17 AEDs associated with a low prevalence of dizziness and
Table 1 Evaluating and treating medically resistant epilepsy
Identifying epilepsy and seizure types vs alternative disorders
Epilepsy
● Partial-onset seizures: simple partial, complex partial, secondary generalized tonic clonic
● Primary generalized epilepsy: childhood and juvenile absence, myoclonic, tonic clonic
● Severe symptomatic (multifocal epilepsy, Lennox-Gastaut) or progressive seizure types
Alternative diagnosis
● Syncope and convulsive syncope
● Psychogenic nonepileptic seizures
● Pain reactions, panic symptoms, dissociative episodes and other psychiatric states, sleep
disorders, narcolepsy
Clues: Careful description of episodes by patient and observers (duration, prodromal symptoms,
responsiveness and behaviors, recovery duration and symptoms)
Gregory L. Krauss and Michael R. Sperling
16 Copyright © 2011 by AAN Enterprises, Inc.
similar symptoms can also be used, such as lamotrigine and levetiracetam.18 Patients often
have dose-limiting CNS-related side effects due to combined effects of AEDs—patients can
often successfully convert rapidly between the old and new medications.
Identify symptomatic causes for medically resistant epilepsy and screen for aggravat-
ing factors Patients with uncontrolled partial-onset seizures may benefit from high-
resolution MRI with thin-section coronal fluid-attenuated inversion recovery (FLAIR)
imaging to identify focal lesions associated with seizures, such as cortical dysgenesis,
vascular abnormalities, and tumors. Cutaneous fibromas, renal lipomas, ataxia, ophthal-
mologic and other abnormalities can be clues suggesting possible genetic and develop-
mental disorders associated with epilepsy. Patients with difficult-to-control seizures often
have seizures triggered by severe stress and exhaustion, illness, sleep deprivation, or alcohol
abuse. These factors are especially important triggers of generalized seizures.19 Some patients
have seizures because they regularly miss or do not take their AED doses—this may be an
expression of abnormal coping or denial of their disorder or can represent a lack of under-
standing of the importance of maintaining steady AED concentrations to prevent seizures.
Table 2 Distinguishing seizures and syncope and other common causes of loss of
awareness 32–34
Seizures Syncope
Other: psychogenic
seizures, pain reactions,
dissociative
Premonitory
symptoms
Psychic or epigastric
aura if partial-onset
seizures
Lightheadedness Often prolonged, pain
may precede
Accompanying
symptoms/signs
Activity arrest,
unresponsiveness,
cyanosis if convulsive
Diaphoresis, pallor, heat
sensation, nausea
Panic, anxiety, pain
Motor signs Rhythmic movements,
focal head/eye
version, chewing eyes
often open, tongue
biting if convulsive
Irregular myoclonus after
onset, brief convulsion if
severe (convulsive
syncope)
Atypical or nonphysiologic
movements (asymmetric
limb jerks, eyelid
fluttering), eyes often
closed
Duration Typically 20 seconds
to 3 minutes
Seconds Variable, often prolonged
(many minutes to hours)
Recovery Rapid to gradual
recovery of alertness
Rapid (disorientation
5 minutes), general
exhaustion
Typically rapid, repetitive
start/stop common
Common
precipitants
None, may vary with
sleep or arousal,
catamenial pattern in
women
Sitting or standing,
dehydration, exhaustion
autonomic activation
(pain or specific stress
trigger)
General emotional and
physical stress, pain
Common
associated
conditions
Prior brain injury or
disorders
Presyncope Psychiatric and cognitive
disorders (mood disorders,
anxiety/panic,
postconcussive syndrome)
Diagnostic tests Abnormal EEG, video
EEG
ECG, tilt table Normal EEG, video EEG,
Personality Assessment
Inventory
Disorders Generalized seizures,
partial-onset seizures,
single seizures
Vasovagal, orthostatic
hypotension, cardiac
syncope (arrhythmia or
loss of cardiac output)
Emotional and cognitive
disorders
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Many patients take AEDs irregularly due to concerns about AED side effects or of pregnancy
risks. These problems are usually resolved by reviewing the diagnosis and treatment
options with patients along with a plan for monitoring for specific drug side effects, such
as irritability with levetiracetam or weight gain with divalproex or concentration diffi-
culty (with all AEDs). Careful attention to ameliorating side effects, use of weekly pill
boxes, smart phone alarms, coupling dosing with dressing or other regular daily activities,
and use of extended-release formulations to reduce dosing frequency can all improve drug
adherence.
Treating medically resistant epilepsy
Three case studies illustrate key principles in managing drug-resistant epilepsy.
Case 1 A 22–year-old woman, with an initial tonic-clonic seizure at age 16, now has 4 seizures
in 2 months, despite treatment with levetiracetam 1,500 mg/day. She previously had seizures and
dizziness during treatment with oxcarbazepine 1,800 mg/day. A previous EEG was normal. She
and her mother describe episodes with features typical of complex partial seizures: a psychic aura
lasting several seconds followed by sudden 30- to 90-second periods of confusion with chewing
Table 3 Possible strategies for treating medically resistant epilepsy
Partial-onset seizures
After failing 2 monotherapy trials with first-line AEDs, e.g., lamotrigine, extended-release
carbamazepine, levetiracetam, oxcarbazepine
● Additional monotherapy trial if high doses of previous AEDs poorly tolerated
● Adjunctive treatment with a complementary AED
● Match AED to patient profiles and needs, e.g., women of childbearing age, elderly patients,
comorbid conditions (e.g., mood disorders, obesity, treatment interactions)
● Minimize combination drug side effects (e.g., dizziness with high doses of oxcarbazepine
and lacosamide) and drug interactions (e.g., increased free carbamazepine concentrations
with divalproex)
● AED options include topiramate, lacosamide, zonisamide, divalproex, phenytoin
● Consider nonmedical therapy: surgery screening, vagal nerve stimulation, ketogenic/Atkins
diet
● Orphan and third-line AED options: clobazam, vigabatrin, barbiturates
Primary generalized epilepsy
After failing 2 monotherapy trials with first-line AEDs, e.g., divalproex, levetiracetam,
lamotrigine (ethosuximide for childhood/juvenile absence epilepsy)
● Consider adjunctive therapy and possible conversion to monotherapy: topiramate,
zonisamide
● Additional adjunctive therapies: clonazepam, acetazolamide, clobazam
Severe symptomatic forms of epilepsy: multifocal, typically multiple seizure types
After failing 2 monotherapy trials with first-line AEDs, e.g., divalproex, levetiracetam,
lamotrigine, carbamazepine
● Consider adjunctive therapy using combinations of broad and narrow spectrum AEDs, e.g.,
topiramate and divalproex, carbamazepine and levetiracetam, levetiracetam and
lacosamide, divalproex and rufinamide
● Nonmedical therapy: vagus nerve stimulation, ketogenic/Atkins diet therapy
● Third-line adjunctive therapies: clonazepam, clobazam, felbamate
Corpus callosotomy (anterior 66% to 80%)
Abbreviation: AED antiepileptic drug.
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motions and fumbling. Detailed questioning elicits a history of a prolonged febrile seizure at age 1
year. A previous MRI is reportedly normal.
Analysis She has typical complex partial seizures—chewing suggests temporal lobe involve-
ment. This is confirmed by a new interictal EEG, which shows left temporal sharp waves. She
strongly desires to be free of seizures in order to drive and to minimize future pregnancy risks.
We can consider increasing the dose of levetiracetam or adding an AED approved for adjunc-
tive treatment of partial-onset seizures. A wide range of other treatment options include
lamotrigine, extended-release carbamazepine, lacosamide, zonisamide, and pregabalin.20 Con-
version to lamotrigine monotherapy is approved and has low risk for birth malformations.
Divalproex (valproic acid) is a suboptimal AED for her, since it is associated with a 10% risk
of birth defects and with weight gain. She is a student and could be treated with low doses of
topiramate but may not wish to risk cognitive impairment with high doses. However, only a
small percentage of patients who fail to respond to 2 or more AEDs become seizure-free.2,21
Most patients with medial temporal lobe epilepsy become seizure-free after anterior temporal
lobectomy or amygdalohippocampectomy.22
After discussing medical and nonmedical treatment options, she is referred for surgical
screening with high-resolution MRI and video-EEG monitoring and begins lamotrigine. Cor-
onal FLAIR MRI demonstrates probable left mesial temporal sclerosis and video-EEG shows
left temporal seizure onset, suggesting she is a good surgical candidate. She continues to
experience complex partial seizures while taking lamotrigine and then has a left anterior
temporal lobectomy, subsequently entering remission. She has a minor decline in verbal
memory after surgery and is able to obtain a driver’s license. When the MRI shows mesial
temporal sclerosis and preoperative verbal memory is impaired, chances are small that surgery
will cause a severe or disabling cognitive deficit.
Case 2 A 21-year-old man has had 3 tonic-clonic seizures in the past year despite treatment
with lamotrigine 600 mg/day and previous treatment with levetiracetam 2,500 mg/day. He
had his first tonic-clonic seizure at age 15, while playing video games. A brain MRI done prior
to referral was normal. There is no family history of seizures.
Analysis Although referred for his tonic-clonic seizures, when asked, the patient reports
having occasional clusters of bilateral arm and neck jerks in the morning. With myoclonic and
tonic-clonic seizures, he is now diagnosed with probable juvenile myoclonic epilepsy (JME).
This is confirmed by an EEG showing interictal 5 Hz generalized polyspike and slow wave
bursts. His treatment adherence is demonstrated by a lamotrigine serum concentration of 14
mg/L (typical target range 4 to 10 mg/L). His seizures do not appear to be provoked by
lifestyle factors such as sleep deprivation or excessive alcohol use. His seizures interfere with
Patients with uncontrolled
partial-onset seizures may
benefit from high-resolution MRI
with thin-section coronal FLAIR
imaging to identify focal lesions
associated with seizures, such
as cortical dysgenesis, vascular
abnormalities, and tumors.
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work and driving. Seizures are usually controlled in JME so continued medical manipulation
is worthwhile.23
He begins treatment with divalproex and has 2 seizures on a dose of 750 mg/day.24 He has
no seizures on divalproex 1,500 mg/day monotherapy in the next year; however, he develops
marked weight gain. He has remained seizure-free since switching to zonisamide 300 mg/
day.25 In this case, ascertainment of the correct diagnosis leads the physician to trying more
medication, with a reasonable prospect of achieving a favorable response.
Case 3 A 25-year-old man with moderate intellectual disability and cerebral palsy has multiple
daily seizures. Most are brief tonic and tonic/atonic seizures with bilateral arm and leg stiffening,
often followed by brief loss of body tone; he also has several seizures each day with unresponsiveness
and asymmetric bilateral shaking, often with left facial contraction. He occasionally falls and is
injured during seizures and must wear a helmet. He is largely confined to a wheelchair. He is
treated with divalproex 500 mg TID (98 mg/L) and clonazepam 0.5 mg TID. He previously had
frequent seizures or was sedated during multiple AED trials, including phenytoin, felbamate, topi-
ramate, lamotrigine, zonisamide, and rufinamide.He had fewer seizures while taking levetiracetam,
but displayed aggressive behavior. An MRI showed mild scattered bilateral subcortical T2 abnor-
malities. EEG shows frequent independent left and right hemisphere and bilateral slow spike and
wave bursts, along with mild diffuse slowing.
Analysis This patient fulfills criteria for diagnosis of Lennox-Gastaut syndrome. Patients
with symptomatic generalized epilepsy often exhibit multiple seizures types, including tonic, com-
plex partial, and tonic-clonic seizures along with significant cognitive impairment. His clinical
condition provides evidence for diffuse brain injury and he is not a candidate for focal resective
surgery. He has not responded to first- and second-line AEDs and will likely require AED poly-
therapy for the foreseeable future. He may benefit from intermittent adjuvant benzodiazepine
treatment, preferably using nonsedating doses, for acute transient seizure exacerbations. He is a
candidate for palliative therapy with vagal nerve stimulation (VNS)26 and also may benefit from
clobazam therapy.27,28 Hemay also cooperate with treatment with the ketogenic/Atkins diet.29 An
anterior (66% to 80%) corpus callosotomy is also a good option, and offers the greatest chance for
substantial reduction in seizure frequency, especially for the tonic and atonic seizures, though it also
has the highest morbidity of the treatments mentioned.30
To minimize his need for emergency department visits, his caregivers were given lorazepam
Intensol 2 mg/mL sublingual solution to treat acute repetitive seizures and a diazepam rectal
formulation to treat occasional prolonged (5 minutes) seizures. Lorazepam Intensol is only
approved for treating anxiety, but has high bioavailability and is frequently used at 1 to 2 mg
sublingual doses for acute seizure treatment. Patients with severe symptomatic epilepsy need
careful monitoring for psychiatric and behavioral symptoms associated with underlying
brain injury, seizures, and AED therapy. The patient had clobazam 10 mg TID substi-
tuted for clonazepam with moderate seizure reduction; he subsequently had VNS placed.
He now has several minor myoclonic and brief focal seizures per week. He no longer falls
In countries with full financial resources,
expensive AEDs and surgery are widely
available, but lack of training to make the
appropriate diagnosis and referral to an
epilepsy center leaves many patients with
inadequate treatment.
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during his seizures and now is permitted to walk independently in his day and residential
program.
Limitations in care
In countries where resources limit access to health care, the above diagnostic considerations
still apply, though the subsequent course of action might differ once a diagnosis of medically
resistant seizures is made. Even if patients cannot afford the newest AEDs, inexpensive drugs
are equally potent. Should inexpensive drugs prove intolerable, then financial limitations may
prevent adequate treatment. Palliative and potentially curative options such as surgery might
not be available. In countries with full financial resources, expensive AEDs and surgery are
widely available, but lack of training to make the appropriate diagnosis and referral to an
epilepsy center leaves many patients with inadequate treatment. In these countries, the wider
selection of AEDs conveys advantages with regard to limiting adverse drug side effects and
expanded treatment options. Patients with medically resistant epilepsy should be counseled
not to drive and often need employment, educational, and psychological support.31
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